Who Pays
HTA, payer evidence, reimbursement models, pricing, and payment design for drug-plus-therapy care.
Approval opens the door; payment decides how many people can walk through it. A therapy can be legal and still unreachable if the medicine, clinical time, rooms, monitoring, and follow-up are not funded.
Psychedelic therapies are difficult for payers because they look like both a medicine and a service. HTA bodies need evidence on clinical benefit, comparators, durability, budget impact, workforce needs, and delivery cost.
Use this section to understand what a reimbursement case has to prove, where standard models may break, and which payment designs could make access more realistic.
Guides and tools
The Personnel-Hours Question in Psychedelic Therapy
A practical guide to staff-hours in psychedelic therapy, and why protocol design, role mix, country rules, and workforce capacity shape cost and access.
Payer Evidence Checklist for Psychedelic Therapies
The evidence payers and HTA bodies need before psychedelic therapies can move from promising trials to coverage decisions.
Psychedelic Therapy Access in Europe: Comparison
Compare ketamine and esketamine licensing, reimbursement, and practical service availability across selected European markets.
EU and UK HTA in 2026: Implications for reimbursement readiness
How EU HTA coordination and UK methods updates affect reimbursement strategy, service-cost modelling, and launch readiness for psychedelic therapies.
Payer and Health Technology Assessments
What payers and HTA bodies need to know before psychedelic therapies can be covered and delivered.
Reimbursement Landscape in Europe
How European reimbursement systems differ, and why national payment decisions shape access after EMA approval.
Europe Access Clocks
Explains the time gap between EMA authorization and real access or reimbursement, using country-level WAIT benchmarks and scenario controls.
Netherlands HTA Access Clock
A Netherlands-specific explainer for the handoff from EMA authorization to ZiN assessment, possible sluis placement, NZa payment design, and practical access.
Psilocybin HTA Uncertainties
A payer-facing map of the clinical, economic, and implementation uncertainties that remain even when psilocybin-assisted therapy shows a positive clinical endpoint.
Psychedelic Therapy Payment Bundle
A service-component map and interactive payment model for reimbursing the medicine, dosing day, therapist time, monitoring, registry work, and follow-up.
Psychedelic Therapy Cost-Effectiveness Model
A reusable cost-utility, cost-effectiveness, and cost-benefit engine for psychedelic-assisted therapy, with illustrative parameter packs, evidence-status labels, and country HTA lenses.
Spravato Access Precedent
A comparator resource for how esketamine moved from EU authorization into different national access outcomes, and what that teaches for psilocybin-assisted therapy.
Real-World Evidence and Registry Design
A registry-design resource for the post-approval evidence questions that trials and economic models rarely settle on their own.
Group Therapy Economics and Implementation
A first-pass resource on when group formats may improve access, when they may add governance burden, and how payment and evidence questions change.
Are Reimbursement Pathways Ready for Licensed Psychedelic Therapies in Europe?
ICPR 2026 talk page with the recording, downloadable slides, slide-by-slide text, and links into Road to Access guides.
Further reading
Regulation (EU) 2021/2282 on health technology assessment
Joint EU HTA framework and timelines relevant to evidence strategy and payer readiness.
European Commission | 15 Dec 2021 | EU | Regulation | Reviewed 17 Apr 2026
Implementation of the Regulation on Health Technology Assessment
framework source relevant to who pays.
European Commission | 12 Jan 2025 | EU | Framework | Reviewed 17 Apr 2026
Guidance on reporting requirements for multiplicity issues and subgroup/sensitivity/post hoc analyses in joint clinical assessments
guidance source relevant to who pays.
European Commission (DG SANTE) | 1 Jan 2024 | EU | Guidance | Reviewed 17 Apr 2026
NICE health technology evaluations manual (PMG36)
guidance source relevant to who pays.
National Institute for Health and Care Excellence (NICE) | 31 Mar 2026 | UK | Guidance | Reviewed 17 Apr 2026
Guide to the methods of technology appraisal 2013 (PMG9)
guidance source relevant to who pays.
National Institute for Health and Care Excellence (NICE) | 4 Apr 2013 | UK | Guidance | Reviewed 17 Apr 2026
NICE real-world evidence framework (ECD9)
guidance source relevant to who pays.
National Institute for Health and Care Excellence (NICE) | 23 Jun 2022 | UK | Guidance | Reviewed 17 Apr 2026
NICE TA854: Esketamine nasal spray for treatment-resistant depression
Technology appraisal with commissioning implications for NHS pathway decisions.
National Institute for Health and Care Excellence (NICE) | 14 Dec 2022 | UK | Guidance | Reviewed 17 Apr 2026
G-BA resolution justification on Esketamine reassessment (D-930)
framework source relevant to who pays.
Federal Joint Committee (G-BA) | 21 Sept 2023 | Germany | Framework | Reviewed 17 Apr 2026
Pakketadvies esketamine neusspray (Spravato) bij therapieresistente depressie
framework source relevant to who pays.
Zorginstituut Nederland | 30 Sept 2020 | Netherlands | Framework | Reviewed 17 Apr 2026
Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg (versie 2024)
guidance source relevant to who pays.
Zorginstituut Nederland | 16 Jan 2024 | Netherlands | Guidance | Reviewed 17 Apr 2026
EFPIA Patients W.A.I.T. Indicator 2023 Survey
analysis source relevant to who pays.
European Federation of Pharmaceutical Industries and Associations (EFPIA) | 1 Jan 2024 | Europe | Analysis | Reviewed 17 Apr 2026
Healthcare expenditure statistics by function, provider and financing scheme
analysis source relevant to who pays.
Eurostat | 1 Nov 2024 | EU | Analysis | Reviewed 17 Apr 2026